Novartis AG’s pioneering new cancer drug on Wednesday won enthusiastic support from a US federal advisory panel, paving the way for approval of the first US gene therapy.
The panel unanimously recommended that the US Food and Drug Administration (FDA) approve the drug — tisagenlecleucel — for patients ages three to 25 with relapsed B-cell acute lymphoblastic leukemia (ALL), the most common form of US childhood cancer.
The drug uses a new technology known as CAR-T, or chimeric antigen receptor T-cell therapy, which harnesses the body’s own immune cells to recognize and attack malignant cells.
Photo: AP
In a clinical trial, 83 percent of patients who had relapsed or failed chemotherapy achieved complete or partial remission three months post infusion. After one year 79 percent of patients were still alive.
Patients with ALL who fail chemotherapy typically have only a 16 percent to 30 percent chance of survival.
“This is a potentially paradigm-changing type of benefit,” said Brian Rini, one of the panelists and a physician at Cleveland Clinic Taussig Cancer Institute.
The FDA is not obliged to follow the recommendations of its advisers, but typically does so. The agency is expected to rule on the drug by the end of September.
Approval of tisagenlecleucel would have implications not only for Novartis, but for companies developing similar treatments, including Kite Pharma Inc, Juno Therapeutics Inc and bluebird bio Inc.
It would also advance a technique scientists have been attempting to perfect for decades and help lift the entire field of cell therapy.
“This will be a historic approval,” said Brad Loncar, chief executive of Loncar Investments, which runs the Loncar Cancer Immunotherapy ETF. “As an investor I’ve never seen anything like it. It’s an entirely new way of treating cancer.”
The product is made by extracting and isolating a patient’s T cells, genetically engineering them to recognize and target cancer cells, and then infusing them back into the patient.
Novartis said the entire process would take 22 days by the time it is launched.
The treatments are given just once and are expected to cost up to US$500,000.
Loncar said approval of tisagenlecleucel would represent an inflection point for investors.
“Any time a new technology crosses the finish line at the FDA, it gets noticed and I think you’ll see a rush of investment and see these therapies be improved over time,” Loncar said.
More than half of patients experienced a serious complication known as cytokine release syndrome, which occurs when the body’s immune system goes into overdrive. Doctors were able to manage the condition and the syndrome caused no deaths.
The FDA expressed concern that the drug could cause new malignancies over the long term.
Panelists generally felt that risk was low and they said Novartis’ risk mitigation proposals were adequate.
Novartis is also testing the drug in diffuse large B-cell Lymphoma, the most common form of non-Hodgkin lymphoma, as is Kite.
BYPASSING CHINA TARIFFS: In the first five months of this year, Foxconn sent US$4.4bn of iPhones to the US from India, compared with US$3.7bn in the whole of last year Nearly all the iPhones exported by Foxconn Technology Group (富士康科技集團) from India went to the US between March and last month, customs data showed, far above last year’s average of 50 percent and a clear sign of Apple Inc’s efforts to bypass high US tariffs imposed on China. The numbers, being reported by Reuters for the first time, show that Apple has realigned its India exports to almost exclusively serve the US market, when previously the devices were more widely distributed to nations including the Netherlands and the Czech Republic. During March to last month, Foxconn, known as Hon Hai Precision Industry
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and the University of Tokyo (UTokyo) yesterday announced the launch of the TSMC-UTokyo Lab to promote advanced semiconductor research, education and talent development. The lab is TSMC’s first laboratory collaboration with a university outside Taiwan, the company said in a statement. The lab would leverage “the extensive knowledge, experience, and creativity” of both institutions, the company said. It is located in the Asano Section of UTokyo’s Hongo, Tokyo, campus and would be managed by UTokyo faculty, guided by directors from UTokyo and TSMC, the company said. TSMC began working with UTokyo in 2019, resulting in 21 research projects,
Ashton Hall’s morning routine involves dunking his head in iced Saratoga Spring Water. For the company that sells the bottled water — Hall’s brand of choice for drinking, brushing his teeth and submerging himself — that is fantastic news. “We’re so thankful to this incredible fitness influencer called Ashton Hall,” Saratoga owner Primo Brands Corp’s CEO Robbert Rietbroek said on an earnings call after Hall’s morning routine video went viral. “He really helped put our brand on the map.” Primo Brands, which was not affiliated with Hall when he made his video, is among the increasing number of companies benefiting from influencer
Quanta Computer Inc (廣達) chairman Barry Lam (林百里) yesterday expressed a downbeat view about the prospects of humanoid robots, given high manufacturing costs and a lack of target customers. Despite rising demand and high expectations for humanoid robots, high research-and-development costs and uncertain profitability remain major concerns, Lam told reporters following the company’s annual shareholders’ meeting in Taoyuan. “Since it seems a bit unworthy to use such high-cost robots to do household chores, I believe robots designed for specific purposes would be more valuable and present a better business opportunity,” Lam said Instead of investing in humanoid robots, Quanta has opted to invest
RSS